Showing 5091-5100 of 5957 results for "".
- ReFocus Eye Health Acquires OptiCare Eye Health & Vision Centershttps://modernod.com/news/refocus-eye-health-acquires-opticare-eye-health-vision-centers/2478105/ReFocus Eye Health has announced the acquisition of OptiCare Eye Health & Vision Centers. Terms of the deal were not disclosed. “We couldn’t be more excited about the surgeons and staff of OptiCare becoming part of the ReFocus family,”
- Vitamin B3 Shows Promise for Glaucoma Patients in Clinical Trialhttps://modernod.com/news/vitamin-b3-shows-promise-for-glaucoma-patients-in-clinical-trial/2478100/A clinical trial led by the Center for Eye Research Australia has shown that vitamin B3 (nicotinamide) could play an important role in protecting against nerve cell damage that leads to blindness in glaucoma, according to a
- MicroOptx Completes Patient Enrollment in Initial Phase of US Pivotal Trial for the Beacon Aqueous Microshunthttps://modernod.com/news/microoptx-completes-patient-enrollment-in-initial-phase-of-us-pivotal-trial-for-the-beacon-aqueous-microshunt/2478098/MicroOptx announced the completion of enrollment in the initial phase of the Beacon Study. This is the FDA investigational device exemption (IDE) clinical trial of the Beacon Aqueous Microshunt. Study participants treated during the initial phase of the interventional, single-arm, open label, mul
- 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-first-patient-dosed-in-phase-1-clinical-trial-of-4d-110-by-intravitreal-injection-for-the-treatment-of-choroideremia/2478092/4D Molecular Therapeutics (4DMT) announced that the first patient has been dosed in the phase 1 clinical trial of 4D-110, a Roche-licensed product candidate, delivered by a single intravitreal injection for Choroideremia. Choroideremia is a blinding and currently untreatable X-linked inher
- COVID-19 Vaccine Candidate Heads To Widespread Testing In U.S.https://modernod.com/news/covid-19-vaccine-candidate-heads-to-widespread-testing-in-u-s/2478083/The COVID-19 vaccine candidate made by the U.S. biotech company Moderna and developed in collaboration with the National Institutes of Health starts its final phase of testing Monday, according to an NPR
- New Novartis Analysis Examines Sustainable Fluid Control of Beovu Compared With Aflibercepthttps://modernod.com/news/new-novartis-analysis-shows-wet-amd-patients-achieved-sustained-fluid-control-faster-with-beovu-versus-aflibercept/2478080/Novartis announced results of a new post-hoc analysis of Beovu (brolucizumab) phase 3 HAWK and HARRIER pivotal trials demonstrating faster sustainable fluid control when compared with aflibercept in patients with wet
- jCyte Announces Phase 2b Results of jCell Therapy in Retinitis Pigmentosahttps://modernod.com/news/jcyte-announces-phase-2b-results-of-jcell-therapy-in-retinitis-pigmentosa/2478078/jCyte Inc. announced promising results from a phase 2b clinical trial of jCell in retinitis pigmentosa (RP), irrespective of genetic subtype. jCell is a first-in-class investigational treatment for RP which has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. In addi
- Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 Phase 2 Clinical Trial in Patients with Macular Edema Due to RVOhttps://modernod.com/news/aerie-pharmaceuticals-reports-positive-topline-results-for-ar-1105-phase-2-clinical-trial-in-patients-with-macular-edema-due-to-rvo/2478079/Aerie Pharmaceuticals reported positive topline results for the company’s phase 2 clinical trial evaluating AR-1105 (dexamethasone intravitreal implant) in patients with macular edema associated with retinal vein occlusion. AR-1105 Phase 2 Highlights
- Novartis Launches “Not Today, Dry Eye” Consumer Campaignhttps://modernod.com/news/novartis-launches-not-today-dry-eye-consumer-campaign/2478073/This month, Novartis launched its new direct-to-consumer commercial and campaign “Not Today, Dry Eye,” which aims to improve awareness of dry eye disease (DED) among consumers. This campaign underscores the fact that inflammation can play an important role in the development and amplification of
- Pepcid As a Coronavirus Remedy? Trump’s $21-Million Gamble Fizzledhttps://modernod.com/news/pepcid-as-a-coronavirus-remedy-trumps-21-million-gamble-fizzled/2478070/As the coronavirus began its deadly march through the world, two well-respected American doctors identified a possible but seemingly unlikely remedy: Pepcid, the heartburn medication found on drugstore shelves everywhere, according to an Associated